How HSP70 helps tumor cells survive and affects the surrounding environment in breast cancer

Dual function of HSP70 in cytoprotection of tumor cells and generation of permissive microenvironment

NIH-funded research Wayne State University · NIH-11124729

This study is looking at how a protein called HSP70 helps triple negative breast cancer cells survive and grow, which could lead to new treatment options that might improve outcomes for patients.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionWayne State University NIH-funded
Lab location1 site (Detroit, United States)
Project IDNIH-11124729 on NIH RePORTER

What this research studies

This research investigates the role of HSP70, a heat-shock protein, in protecting tumor cells from death and influencing the tumor microenvironment in triple negative breast cancer (TNBC). The study aims to understand how HSP70 contributes to the aggressive nature of TNBC by promoting cancer stem cell properties and creating an immunosuppressive environment that hinders effective immune responses. By examining the molecular mechanisms involved, the research seeks to identify potential therapeutic targets that could improve patient outcomes. Patients may benefit from insights gained regarding the tumor's behavior and potential new treatment strategies.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with triple negative breast cancer who may be experiencing disease progression.

Not a fit: Patients with non-breast cancer types or those whose tumors do not exhibit aggressive characteristics may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapies that enhance the immune response against aggressive breast cancer.

How similar studies have performed: Previous research has shown promising results in targeting the tumor microenvironment and immune modulation in cancer treatment, suggesting that this approach could be effective.

Where this research is happening

Detroit, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.